MX2022004638A - Proteina portadora mutante sitio dirigida y su uso en la preparacion de la vacuna. - Google Patents

Proteina portadora mutante sitio dirigida y su uso en la preparacion de la vacuna.

Info

Publication number
MX2022004638A
MX2022004638A MX2022004638A MX2022004638A MX2022004638A MX 2022004638 A MX2022004638 A MX 2022004638A MX 2022004638 A MX2022004638 A MX 2022004638A MX 2022004638 A MX2022004638 A MX 2022004638A MX 2022004638 A MX2022004638 A MX 2022004638A
Authority
MX
Mexico
Prior art keywords
site
carrier protein
vaccine
directed mutation
preparation
Prior art date
Application number
MX2022004638A
Other languages
English (en)
Inventor
Haomeng Wang
Qiaoling Yan
Shoubai Chao
Huihua Mao
Tao Zhu
Original Assignee
Cansino Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cansino Biologics Inc filed Critical Cansino Biologics Inc
Publication of MX2022004638A publication Critical patent/MX2022004638A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Abstract

La presente invención proporciona una proteína portadora mutante sitio dirigida y su uso en la preparación de una vacuna; un aminoácido en al menos un sitio de la proteína portadora se muta en un aminoácido no natural que contiene un grupo final azida o alquil;la proteína portadora mutante sitio dirigida dela presente invención es capaz de evitar la reticulación excesiva con un antígeno polisacárido y puede ser utilizada para preparar una vacuna conjugada de polisacáridos y proteínas.
MX2022004638A 2019-10-15 2020-09-25 Proteina portadora mutante sitio dirigida y su uso en la preparacion de la vacuna. MX2022004638A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910978406.XA CN110845587B (zh) 2019-10-15 2019-10-15 一种定点突变的载体蛋白及其在制备疫苗中的用途
PCT/CN2020/117825 WO2021073402A1 (zh) 2019-10-15 2020-09-25 一种定点突变的载体蛋白及其在制备疫苗中的用途

Publications (1)

Publication Number Publication Date
MX2022004638A true MX2022004638A (es) 2022-07-11

Family

ID=69596763

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004638A MX2022004638A (es) 2019-10-15 2020-09-25 Proteina portadora mutante sitio dirigida y su uso en la preparacion de la vacuna.

Country Status (12)

Country Link
US (1) US20230111095A1 (es)
EP (1) EP4047013A4 (es)
JP (1) JP7366333B2 (es)
KR (1) KR20220082035A (es)
CN (1) CN110845587B (es)
AU (1) AU2020366472B2 (es)
BR (1) BR112022007213A2 (es)
CA (1) CA3154849A1 (es)
CO (1) CO2022006035A2 (es)
EC (1) ECSP22038109A (es)
MX (1) MX2022004638A (es)
WO (1) WO2021073402A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110845587B (zh) * 2019-10-15 2021-06-29 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
CN111533792B (zh) * 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
CA3221075A1 (en) * 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN113651876B (zh) * 2021-08-18 2024-02-02 成都齐碳科技有限公司 孔蛋白单体的突变体、蛋白孔及其应用
CN114456275B (zh) * 2022-01-27 2023-05-12 苏州大学 一种多位点单泛素修饰组蛋白的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200900899B (en) * 2006-08-07 2010-07-28 Harvard College Protein matrix vaccines and methods of making and administering such vaccines
WO2009035494A2 (en) * 2007-07-30 2009-03-19 The Scripps Research Institute Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease
EP2966061B1 (en) * 2011-03-04 2017-05-03 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
CN102159032B (zh) 2011-03-25 2013-06-19 罗小亚 一种采用模切机制造挠性印刷线路板的工艺方法
CN103110940B (zh) * 2013-02-06 2015-06-03 中国科学院过程工程研究所 一种基于点击化学的肺炎多糖结合疫苗及其制备方法
JP6967221B2 (ja) * 2015-08-19 2021-11-17 国立研究開発法人理化学研究所 非天然アミノ酸導入抗体
CN105175549B (zh) 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
CN106929482A (zh) 2015-12-31 2017-07-07 北京大学 定点突变的流感病毒、其活疫苗及其制备方法和应用
JP7186166B2 (ja) * 2016-12-30 2022-12-08 バックスサイト・インコーポレイテッド 非天然アミノ酸とのポリペプチド抗原接合体
CN108904798A (zh) * 2018-07-17 2018-11-30 成都安特金生物技术有限公司 一种多糖蛋白结合疫苗及其鉴别方法
CN110845587B (zh) * 2019-10-15 2021-06-29 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途

Also Published As

Publication number Publication date
CN110845587A (zh) 2020-02-28
JP7366333B2 (ja) 2023-10-23
KR20220082035A (ko) 2022-06-16
CN110845587B (zh) 2021-06-29
AU2020366472B2 (en) 2024-01-04
CA3154849A1 (en) 2021-04-22
ECSP22038109A (es) 2022-07-29
CO2022006035A2 (es) 2022-05-20
WO2021073402A1 (zh) 2021-04-22
US20230111095A1 (en) 2023-04-13
BR112022007213A2 (pt) 2022-08-02
JP2022552403A (ja) 2022-12-15
AU2020366472A1 (en) 2022-05-12
EP4047013A1 (en) 2022-08-24
EP4047013A4 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
MX2022004638A (es) Proteina portadora mutante sitio dirigida y su uso en la preparacion de la vacuna.
TWD207304S (zh) 電池組的端子台
CY1123555T1 (el) Συμπλοκο πρωτεϊνης ιντερλευκινης 15 και χρηση αυτου
PH12020551261A1 (en) Il-15 conjugates and uses thereof
TWD203688S (zh) 電連接器
TWD202030S (zh) 連接器端子
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
TWD207305S (zh) 電池組的端子台
MX2020007495A (es) Formulacion de adenovirus del grupo b.
TWD205347S (zh) 連接器端子
TWD206399S (zh) 電連接器
MX2021005293A (es) Conjugados de interleuquina 10 y usos de los mismos.
TWD214309S (zh) 電池組接口部
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
TR201809262A2 (tr) Farkli uçlara sahi̇p i̇ki̇ tarafli kullanilabi̇len cerrahi̇ penset
TWD211066S (zh) 連接器之部分
TWD204989S (zh) 連接器
MY189759A (en) Conjugate of finasteride with peptide
MX2022005251A (es) Conjugados de interleuquina 10 y sus usos.
TWD211067S (zh) 連接器之部分
TWD211064S (zh) 連接器之部分
TWD211045S (zh) 連接器之部分
TWD198590S (zh) 電連接器之部分
TWD204990S (zh) 連接器